How do we manage high-grade T1 bladder cancer?: conservative or aggressive therapy?

Cited 12 time in scopus
Metadata Downloads
How do we manage high-grade T1 bladder cancer?: conservative or aggressive therapy?
S J Yun; Seon-Kyu Kim; W J Kim
Bibliographic Citation
Investigative and Clinical Urology, vol. 57, no. S1, pp. S44-S51
Publication Year
High-grade T1 bladder cancer has a poor prognosis due to a higher incidence of recurrence and progression than other nonmuscle invasive bladder cancer; thus patients with high-grade T1 have to be carefully monitored and managed. If patients are diagnosed with high-grade T1 at initial transurethral resection (TUR), a second TUR is strongly recommended regardless of whether muscle layer is present in the specimen because of the possibility of understating due to incomplete resection. Since high-grade T1 disease shows diverse clinical courses, individual approaches are recommended for treatment. In cases with low risk of progression, cystectomy could represent overtreatment and deteriorate quality of life irreversibly, while, in those with high risk, bacillus Calmette? Guerin (BCG) therapy may worsen survival by delaying definitive therapy. Therefore, a strategy for predicting prognosis based on the risk of progression is needed for managing high-grade T1 disease. Molecular risk classifiers predicting the risk of progression and response to BCG may help identify the optimal management of high-grade T1 disease for each individual.
Disease progressionTherapeuticsUrinary bladder neopla
Korea Soc-Assoc-Inst
Appears in Collections:
Aging Convergence Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.

Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.